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Abstract
Objective: We examined the association of HIV-1 subtypes with disease progression based on three viral gene regions.
Design: A prospective HIV-1 clinical cohort study in rural Uganda.
Methods: Partial gag, env and pol genes were sequenced. Cox proportional hazard regression modelling was used to
estimate adjusted hazard ratios (aHRs) of progression to: CD4#250, AIDS onset and death, adjusted for sex, age and CD4
count at enrolment.
Results: Between 1990 and 2010, 292 incident cases were subtyped: 25% had subtype A, 45% had D, 26% had A/D
recombinants, 1% had C and 4% were other recombinant forms. Of the 278 incident cases included in the disease
progression analysis, 62% progressed to CD4#250, 32% to AIDS, and 34% died with a higher proportion being among
subtype D cases. The proportions of individuals progressing to the three endpoints were significantly higher among
individuals infected with subtype D. Throughout the study period, individuals infected with subtype D progressed faster to
CD4#250, adjusted HR (aHR), (95% CI) = 1.72 (1.16–2.54), but this was mainly due to events in the period before
antiretroviral therapy (ART) introduction, when individuals infected with subtype D significantly progressed faster to
CD4#250 than subtype A cases; aHR (95% CI) = 1.78 (1.01–3.14).
Conclusions: In this population, HIV-1 subtype D was the most prevalent and was associated with faster HIV-1 disease
progression than subtype A. Further studies are needed to examine the effect of HIV-1 subtypes on disease progression in
the ART period and their effect on the virological and immunological ART outcomes.
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Introduction
There are two types of Human Immunodeficiency Virus (HIV);
HIV-1 which has a global distribution and HIV-2 that is mainly
confined to West and Central Africa [1]. HIV-1 is divided into
groups M (Major), N (Non-M non-O), O (Outlier) and a new
group named P (pending the identification of further human cases)
recently identified in two Cameroonian patients [2,3]. Group M is
further divided into 9 genetic subtypes (A–D, F–H, J–K) with
subtype A further subdivided into 4 sub-subtypes (A1, A2, A3, A4)
and subtype F into 2 sub-subtypes (F1 and F2). At least 55
circulating recombinant forms (CRFs) along with a myriad of
unique recombinant forms (URFs) have been identified (http://
www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html,
June 2013). Majority of HIV-1 subtypes, CRFs and URFs are in
Sub-Saharan Africa which is the worst affected by the HIV
epidemic. The impact and implications of the high genetic
diversity of HIV on transmission, disease progression, antiretro-
viral therapy (ART), vaccine design and development have been
reported in a number of studies however more research is required
to fully understand these implications.
One study in Uganda reported that subtype A had a
significantly higher transmission rate than subtype D, partially
explaining the observed increase in prevalence of subtype A in
some populations [4,5]. We have however reported no significant
changes in subtype proportions in our populations over time [6,7].
Other studies in Tanzania and Uganda have shown that subtype
D is associated with faster disease progression compared to other
subtypes and recombinant forms [8–13]. In these studies,
individuals infected with subtype D had significantly higher rates
of CD4+ T-cell loss and a shorter progression time to AIDS or
death than other subtypes and recombinants. Explanations for
these observations are not fully understood, however, a study in
Uganda showed that individuals having non-AIDS clinical status
were more likely to be infected with X4 subtype D viruses than X4
subtype A viruses [14]. Slow or non syncytium-inducing (NSI)
viruses have been shown to use the fifth receptor for CC
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chemokines (CCR5) for viral entry while rapid or high syncytium-
inducing (SI) viruses use the fourth receptor for CXC chemokines
(CXCR4) [15,16]. This observation could possibly explain the
faster disease progression rates in subtype D infected individuals.
A study comparing HIV disease progression in ethnic Africans
and Swedes found no differences in disease progression between
subtype A and D, however the small sample size might have biased
their results [17]. Observed differences in disease progression and
transmission rates between subtypes may in part explain the
changing trends in subtype distribution in some populations but
migration may also contribute to the changing subtype distribution
[5,18]. In Uganda, subtype D has been associated with develop-
ment of HIV dementia in individuals with advanced HIV
immunosuppression and at risk of developing HIV-associated
cognitive impairment [19]. In addition, HIV-1 subtypes in
Uganda have also been shown to have an effect on response to
antiretroviral therapy [20] where subtype D was associated with
faster CD4+ T-cell decline before ART and was shown to lead to a
higher rate of virological failure after ART initiation. The
virological and immunological mechanisms for this observation
remain unknown.
Additionally, circulating HIV subtypes in a particular popula-
tion have implications on the design and development of a
protective vaccine [21–23]. Surveillance of circulating subtypes
and recombinants may therefore be important for clinical
management and preparation for vaccine studies. One shortfall
is that most of the earlier studies inferred HIV-1 subtype by
analysis of one gene to determine the effect of HIV-1 subtypes on
disease progression. In this work we report on the subtype
distribution and the effect of these subtypes on disease progression
in a prospective population-based clinical cohort in rural South-
west Uganda by subtyping partial env, gag and pol genes. We further
assess for any differences on the effect of subtypes on disease
progression in the periods before and after the introduction of
ART in this population.
Methods
Study Population
The study participants were HIV incident ART naive
individuals aged 13 years and above. Participants were enrolled
in a prospective HIV-1 clinical cohort study in rural Uganda
between 1990 and 2010. The clinical cohort was established to
study the natural history of HIV-1 infection [24] and is nested in a
larger general population cohort (GPC) that was established to
study the population dynamics of the HIV epidemic [25,26]. HIV
incident cases with estimated dates of seroconversion were
identified from the GPC and invited to enrol in the clinical
cohort if the interval between last negative and first positive HIV
test was less than 4 years. Study participants were routinely
followed up quarterly, but also attended the clinic whenever
necessary. The World Health Organisation (WHO) clinical staging
was done at every routine visit, both by clinicians, and through a
computer-based algorithm. Vital status was ascertained every year
for participants who did not attend the clinic for follow-up. Since
2004 free ART has been provided to all eligible study participants
according to the Ministry of Health National ART guidelines
[27,28].
Laboratory Methods
CD4 cell counts measurements. Throughout the study,
CD4 cell counts measurements were done at enrolment and every
6 months for HIV positive participants not on ART. Between
1990 and 1994, CD4 cell counts were measured in an external
laboratory by Flow Cytometry method while between 1995 and
Table 1. Characteristics of HIV-1 incident cases in the cohort: 1990–2010.
Characteristic Males Females Total P-value
Total 127 (43%) 165 (57%) 292 (100) 0.01*
Estimated age (years)
At HIV sero-conversion
Mean (SD) 35 (12.5) 30 (12.4) 32 (12.6) ,0.01+
Median (IQR) 31 (25–41) 28 (21–35) 30 (23–37) ,0.01&
Range 18–79 13–72 13–79
At first positive HIV test result
Mean (SD) 35 (12.4) 31 (12.2) 33 (12.5) ,0.01+
Median (IQR) 31 (26–41) 28 (21–35) 30 (23–38) ,0.01&
Range 18–79 14–72 14–79
At enrolment in cohort
Mean (SD) 35 (12.5) 31 (12.2) 33 (12.5) ,0.01+
Median (IQR) 31 (26–41) 28 (21–35) 30 (23–38) ,0.01&
Range 19–79 14–72 14–79
Virological and immunological status at enrolment
Mean (SD) viral load (log10 copies/ml) (n = 122) (n = 155) (n = 277) 0.167
+
4.63 (0.92) 4.53 (0.80) 4.57 (0.85)
Median (IQR) CD4 cell counts (cells/mm3) 576 (459–758) 587 (425–895) 577 (435–845) 0.65&
*one-sided two sample test of proportion.
+one-sided t-test.
&Kruskal-Wallis test.
doi:10.1371/journal.pone.0071768.t001
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2010, CD4 cell counts were measured in our laboratory using the
FACSCount method (Becton Dickinson, San Jose, CA, USA).
Viral load measurements. Since 1996, viral loads were
measured at enrolment and annually for all HIV positive
participants not on ART. Prior to January 2004 we used the
VERSANT RNA 3.0 (Bayer, Bayer HealthCare, NY, USA) assay
(lower detection limit of 50 copies/ml). From October 2007 we
used the Amplicor MONITOR 1.5 (Roche, Roche Molecular
Systems, NJ, USA) assay (lower detection limit of 400 per copies/
ml).
Sample collection and HIV-1 subtyping. At enrolment, all
HIV-1 incident cases had 4 mls of blood collected in an EDTA
tube. The samples were transported within 24 hours to the
Medical Research Council/Uganda Virus Research Institute
(MRC/UVRI) Uganda Research Unit on AIDS Basic Science
laboratory in Entebbe for testing, processing and storage of plasma
and packed cells. A total of 209 samples from incident cases
enrolled between 1990 and 2003 were analysed as follows: Proviral
DNA was extracted from whole blood using a Puregene kit
(Gentra Systems Inc., North Carolina, USA), according to
manufacturer’s instructions. The DNA was amplified directly
(without cloning) by nested PCR in both the v3/v4 region of the
env gene (approximately 400 bp) and a region of the gag gene
encompassing most of both p17 and p24 (approximately 720 bp).
Sequencing and phylogenetic analysis using the fastDNAml and
Treecon package softwares was done as previously reported
[29,30]. Samples from 83 incident cases enrolled between 2004
and 2010 were subtyped by sequencing and phylogenetic analysis
in the pol-IN, gp-41 and gag-p24 genes and subtypes assigned using
the REGA HIV-1 subtyping tool as previously described [31,32].
Different genomic regions were sequenced in the two study periods
due to differences in the study objectives of the two periods and
cost of the assays.
Statistical Analysis
Study participants characteristics were examined, tabulated and
the proportions of males and females were compared using the
one-sided two-sample test of proportions. Comparison of means
and medians of various characteristics by gender and HIV-subtype
was done using the one-sided t-test and Kruskal-Wallis test
respectively. Study endpoints were defined as: CD4#250 cells/
mm3, WHO clinical stage 4 (AIDS) and death before (1990–2003)
and after ART introduction (2004–2010). Participants were
eligible for inclusion in analysis as events if they had not accessed
ART prior to reaching the end point. Those who accessed ART
prior to the end point where censored at the ART start date. For
the progression to CD4#250 outcome, we also considered
individuals who started ART prior to reaching CD4#250 as
events for this outcome with ART start date as the event time.
Cox proportional hazard regression models were used to
estimate hazard ratios (HRs) of disease progression to each
endpoint for the HIV-1 subtypes adjusting for sex, age at
seroconversion and baseline CD4 cell count. As a standard
practice, baseline viral load was fitted as a logarithm-transformed
variable. Baseline CD4 cell count depicted non-linear relationship
with the various outcomes and was therefore fitted as a square
root, square and cube transformed variable. Subsequent viral load
and CD4 cell counts were not included in the model since these
are proxy for disease progression.
Ethics Statement
The study was approved by the Uganda Virus Research
Institute Institutional Review Board and the Uganda National
Council for Science and Technology. For study participation,
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specimens collection and subsequent analysis, at enrolment all
participants aged 18 years and above gave signed or thumb-
printed written informed consent, participants aged 13–17 years
gave formal assent and in addition a parent or guardian gave
signed or thumb-printed written informed consent. Confidentiality
procedures were adhered to throughout the study.
Results
Participants’ Enrolment Characteristics
Between 1990 and 2010, 590 HIV incident cases were invited to
enrol in the clinical cohort, of whom 382 (65%) were enrolled. Of
those enrolled, 292 (76%) met the study inclusion criteria. We
report findings from the 292 HIV-1 subtyped cases, of which 57%
were female. At HIV seroconversion, first HIV positive test and
enrolment in the cohort, males were significantly older than
females (p,0.01). At enrolment, there were no significant gender
differences in mean viral load and median CD4 cell count
(Table 1).
HIV-1 Subtype Distribution and Baseline Virological and
Immunological Status
Subtype D was the most prevalent in all the three regions of env,
gag and pol and in the combined regions. During the pre-ART
(1990–2003) and whole (1990–2010) periods, the proportion of
subtype D incident cases was significantly higher than that of both
subtype A and A/D recombinants (p,0.01). In the combined
region, HIV-1 subtypes were similarly distributed over the whole
and in the pre-ART periods, however, in the ART period there
was a slight increase in subtype A cases (Table 2). The subtype and
disease progression analysis was based on the 278 (95% of the
subtyped) cases of subtypes A, D, and A/D recombinants. The
mean baseline viral load (log10 copies/ml) was significantly
different among the three subtypes A, D and A/D recombinants
(one way anova p-value = 0.01). Subtype A cases had the lowest
mean baseline viral load, followed by A/D recombinants and then
subtype D cases. There were no significant differences in the
distribution of baseline CD4 cell counts between the HIV subtypes
(Table 2).
Effect of HIV-1 Subtypes on Disease Progression
By December 2010, of the 278 cases, 62% had progressed to
CD4 count #250 and 32% to AIDS, while 34% had died. Before
ART introduction and over the whole study period, the
proportion of cases progressing to any of the three outcomes was
highest among subtype D cases followed by A/D recombinants
(Table 3). During the ART period, there were only two cases valid
for inclusion in the AIDS and death outcome analyses, therefore
further analyses for these outcomes were not performed in this
period. Subtype D cases significantly progressed faster to
CD4#250 than subtype A cases during both the pre-ART period
[adjusted Hazard Ratio (aHR)= 1.78, 95% Confidence Interval
(95% CI): 1.01–3.14] and the whole period [aHR=1.72, (95% CI:
1.16–2.54)]. During the three analysis periods, females progressed
faster to CD4#250 than males, while in the pre-ART and whole
study period, older age at seroconversion was significantly
associated with faster progression to CD4#250. Higher baseline
CD4 cell count was protective in all the three analysis periods
(Table 4, Part 1).
Over the whole study period, HIV-1 A/D recombinant cases
progressed faster to AIDS than subtype A cases [aHR=1.88,
(95%CI: 1.01–3.48)]. During both the pre-ART and whole
periods, higher baseline CD4 cell count offered protection against
progression to AIDS at a significant adjusted rate of 17% during
the pre-ART period (Table 4, Part 2). During the pre-ART
period, subtype D cases had a non-significant faster progression to
death than subtype A cases [aHR=1.83, (95% CI: 0.95–3.55)].
Older age at seroconversion was significantly associated with faster
progression to death during both the pre-ART and whole periods.
High baseline CD4 cell count offered better survival (Table 4, part
3).
Discussion
In this rural Ugandan population, over a two decades study
period we found that individuals infected with HIV-1 subtype D,
the most prevalent subtype, had a significantly faster disease
progression to CD4 cell counts #250 cells/mm3 than those
infected with subtype A. Although non-significant, HIV-1 subtype
D cases also had a faster disease progression to AIDS and to death
than subtype A cases. Compared to subtype A cases, A/D
recombinants cases had a significant faster disease progression to
AIDS, but the progression to CD4 cell counts #250 cells/mm3
and death was not significantly faster. Female gender was
associated with a significantly faster disease progression to CD4
cell counts #250 cells/mm3 than among males. Older age at
seroconversion and lower baseline CD4 cell counts were
significantly associated with faster disease progression to CD4 cell
counts#250 cells/mm3 and death. After the introduction of ART,
the association between HIV subtype and disease progression
became non-significant, though we did not have enough events to
assess progression to AIDS and death during this period.
The strength of our study was the long follow-up time with
regular clinical and laboratory data that allowed us to examine
disease progression over a two decades period. Our study was
however limited by our failure to control for host genetic factors
Table 3. Number (proportion (%)) of participants progressing to each outcome by HIV-1 subtype.
Outcome: CD4#250 Outcome: WHO-stage 4: AIDS Outcome: Death
Subtype Pre-ART ART period Whole period Pre-ART ART period Whole period Pre-ART ART period Whole period
A 18 (19) 14+5*(24) 37 (21) 11 (18) 5+0*(19) 16 (18) 14 (19) 6+1*(32) 21 (22)
D 49 (52)&& 26+14*(51) 89 (51)&& 28 (46)& 13+1*(52) 42 (48)& 36 (49)& 12+0*(55) 48 (51)&&
A/D 28 (29) 15+4*(24) 47 (27) 22 (36) 7+1*(30) 30 (34) 23 (32) 2+1*(14) 26 (27)
Total 95 (100) 55+23* (100) 173 (100) 61 (100) 25+2*(100) 88 (100) 73 (100) 20+2* 95 (100)
*Number not valid for analysis in the ART period; sero-converted after ART roll out.
&&Proportion of subtype D is higher than that of A (p#0.01) and of A/D (p,0.05).
&Proportion of subtype D is higher than that of A (p#0.05).
doi:10.1371/journal.pone.0071768.t003
HIV Subtypes and Disease Progression
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like HLA, which might influence HIV disease progression. In
addition, we did not have HIV-1 subtype data on 51% of the
incident cases in this population (208 not enrolled in the cohort
and 90 enrolled but not subtyped). This could have introduced a
selection bias that might have affected the observed results.
Though we inferred HIV-1 subtype by sequencing partial env, gag
and pol genes, this could have possibly misclassified some real
recombinants as pure subtypes. Also there may have been a
possibility that some reported recombinants could have been HIV-
1 dual/multiple infections (infection with more than one HIV-1
subtype or strain), which have been associated with faster disease
progression [32,33]. Therefore whole genome sequencing could
have been the ideal method to infer subtype.
An earlier study did not find association between HIV subtypes
and disease progression leading to a conclusion that probably
determination of genetic HIV subtype had little value in routine
clinical patient care. This study was however limited by a small
sample size and short follow-up [17,34]. Our findings are in
conformity with a study in a neighbouring district which reported
shorter survival times among individuals infected with subtype D
and A/D recombinants compared to those infected with subtype A
[10]. Other studies on the effect of HIV-1 subtypes on disease
progression have also reported that HIV subtype D is associated
with faster disease progression compared to subtype A [8–10,12–
14,35]. In Senegal, women infected with non-A HIV subtypes
were 8 times more likely to progress to AIDS than those infected
with the predominant subtype A [36].
The faster rates of CD4 T-cell decline associated with subtype D
and a higher probability of having an X4 virus in subtype D
infections (compared to subtype A) had earlier been given as
possible explanations for the faster disease progression among
those infected by subtype D than subtype A [8,14,37]. However, a
later study investigating the number of CD4+ T cells expressing
CCR5 or CXCR4 found specific alterations in the abundance of
CD4+/CCR5+ and CD4+/CXCR4+ T cells and in immune
proteins concentrations across different HIV clades. The authors
concluded that these changes were unlikely to explain the
differences observed in disease progression between subtype A
and D cases [38].
Although for the whole study period we found a faster disease
progression to CD4 cell counts #250 cells/mm3 among individ-
uals infected with subtype D than those infected with subtype A,
this was mainly due to the observations in the period before ART
introduction. In the ART period, we did not find association
between HIV-1 subtype and disease progression to CD4#250
cells/mm3 or AIDS, because individuals started ART before these
endpoints were reached. The faster progression of subtype D cases
to CD4#250 cells/mm3 implies that they will initiate ART earlier
than subtype A cases.
The odds of progressing to AIDS and death were not
significantly higher among subtype D compared to subtype A
possibly because of the lower proportion of participants progress-
ing to these end points than that progressing to CD4 cell counts
#250 cells/mm3. In Uganda, an AIDS diagnosis is an indepen-
dent ART eligibility criterion, while the CD4 cell count threshold
for ART eligibility has changed from equal to or less than 200
cell/mm3 at the start of ART roll out in 2004 to equal to or less
than 250 cells/mm3 in 2008.
Our finding that older age at seroconversion is associated with
faster disease progression is in agreement with our earlier findings
[39] and with findings from the neighbouring Rakai district [11],
Zambia [40] and Greece [41]. In our study, 57% of patients were
female, this finding is not surprising and is supported by the
WHO/UNAIDS estimates in 2010 when women constituted 59%
of all HIV infected patients in sub-Saharan Africa [42]. Our
finding that females had a faster disease progression to CD4 cell
counts #250 cells/mm3 than males is in conformity to what has
been reported from Zambia [40]. Although the biological
mechanisms of the gender difference in HIV disease progression
remain unclear, reports from the USA have also reported that
women progressed faster and had more rapid declines in CD4 cell
counts than men [43,44]. The findings that lower baseline CD4
cell counts is associated with faster disease progression to CD4 cell
counts #250 cells/mm3 and death are similar to those reported
from a Ugandan seroprevalent HIV cohort [45] and a commu-
nity-based cohort in Zambia [40].
Conclusion
In this population, HIV-1 subtype D was the most prevalent
and was associated with faster HIV-1 disease progression than
subtype A. Further studies are needed to examine the effect of
HIV subtypes on disease progression in the ART period and their
effect on ART virological and immunological outcomes.
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